Chinese Biotechs Lining Up For Cross-Straits IPOs In Taiwan
This article was originally published in PharmAsia News
Executive Summary
Thanks to surging valuations, a relaxed profitability rule and a familiar business culture, Taiwan offers allure to mainland biotechs aspiring to raise funds across the strait.